SAN FRANCISCO, June 17, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the appointment of Donald R. Joseph as Chief Legal Officer. Mr. Joseph brings to KaloBios almost 20 years of biopharmaceutical industry experience and has worked in both public and private companies, as well as major global health non-profit organizations. (Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO) "Don has a long and successful track record as a general counsel and senior executive and his knowledge and experience will serve KaloBios well," said David Pritchard, KaloBios President and Chief Executive Officer. "Moreover, his primary therapeutic areas of experience, which include oncology, infectious diseases, and antibody technology, are directly relevant to KaloBios' own pipeline of patient-targeted, first-in-class monoclonal antibodies. I am very pleased to welcome Don to the KaloBios management team." Mr. Joseph has served as general counsel, corporate secretary and in other senior management roles at biopharmaceutical companies, including Abgenix and Renovis. In addition to his legal responsibilities, Mr. Joseph has also played a significant role in numerous financings, mergers and acquisitions, and strategic alliances. "I am very pleased to be joining KaloBios at this important time in its growth and development as an emerging biopharmaceutical company. The KaloBios pipeline and patient-targeted approach are very exciting. I am looking forward to contributing to the further success of the company," Mr. Joseph commented. Most recently, Mr. Joseph has been a senior executive in global health organizations. He was CEO of BIO Ventures for Global Health (BVGH) from February to November 2012 and COO from April 2010 to January 2012. He is currently Chairman of the BVGH board of directors. He has also served as COO at the Institute for OneWorld Health, a non-profit drug development company. In both organizations, he was also responsible for the legal function in addition to his other responsibilities. Before entering the life sciences industry, Mr. Joseph practiced business law for a number of years in major firms, including as an international partner at Baker & McKenzie, one of the world's largest law firms. Mr. Joseph received his J.D. degree from the University of Texas School of Law, with honors. About KaloBios KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies (mAbs) designed to treat serious life-threatening or debilitating disease for which there is an unmet medical need with a clinical focus on serious respiratory diseases and cancer.